GIFT Nifty on the NSE IX traded 48 points, or 0.24 percent, down at 19,857.50 on September 21, indicating that Dalal Street was likely to have a bad start on Thursday. These stocks will be the subject of today’s attention for a variety of reasons.
Infosys: To create generative AI applications and solutions, the major IT company has partnered with NVIDIA.
EMS: On Thursday, the water and sewage infrastructure provider EMS will list. According to ipowatch.com, the stock is trading for a premium of 39% on the black market at the issue price of Rs 211.
SJVN: The government will offer for sale 96.667 million shares, or 2.46 percent of the corporation, with the possibility of selling an additional 2.46 percent. The full 4.92 percent stake may be sold for more than Rs 650 crore at the floor price of Rs 69 per share. Today (Sept. 21) is the opening day for non-retail investors, and Friday, Sept. 22, is for retail investors.
Cipla: Five observations were made in Form 483 after a USFDA inspection of InvaGen Pharmaceuticals Inc.’s manufacturing plant in New York, USA, a corporate wholly-owned subsidiary. No repetition or data integrity (DI) observations have been made. According to a statement released by Cipla, the business will fully resolve these within the allotted time.
State Bank of India, KFin Technologies: SBI has replaced the current RTA Alankit Assignments with KFin Technologies as the Registrar and Share Transfer Agent (RTA).
The Sheela FoamThe QIP Committee has chosen to launch the QIP on September 20 with an equity share floor price of Rs 1,133.99. On September 25, it will convene to discuss and approve the QIP issuance price.
The Reserve Bank of India has given HDFC Asset Management Company permission to purchase a combined stake of up to 9.5% of DCB Bank. The RBI has instructed the AMC to purchase the shares within a year of the clearance date.
Apollo Tyres: At its factory in Limda, Gujarat, the firm has ceased manufacture of bias and OTR tires.
Clindamycin Phosphate Gel USP, 1%, a medication used to treat acne, has been given final clearance by the US Food and Drug Administration (USFDA) to Zydus Lifesciences. In the United States, sales of Clindamycin Phosphate Gel USP, 1% were $37 million per year (IQVIA MAT, July 2023).
The Board of Directors of Shree Renuka Sugars will convene on September 23 to discuss and decide whether to engage into a legally binding agreement for the purchase of 100% equity shares in a sugar manufacturing business in Uttar Pradesh, India.
